Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer? Cover

.blurhash-client-img { display: none !important; }

Does additional HIPEC help after CRS in peritoneal disseminated gastric cancer?

Current Issues in Pharmacy and Medical Sciences

Volume 30 (2017): Issue 4 (December 2017)

By: Beate Rau, Eva Pachmayr, Dusan Klos, Peter Thuss-Patience and Andreas Brandl

Open Access

|Mar 2018

Authors

Beate Rau

beate.rau@charite.de

Chirurgische Klinik, Charité, Universitätsmedizin Berlin, Berlin, Germany

Eva Pachmayr

Chirurgische Klinik, Charité, Universitätsmedizin Berlin, Berlin, Germany

Dusan Klos

Chirurgische Klinik, Charité, Universitätsmedizin Berlin, Berlin, Germany

Peter Thuss-Patience

Chirurgische Klinik, Charité, Universitätsmedizin Berlin, Berlin, Germany

Andreas Brandl

Chirurgische Klinik, Charité, Universitätsmedizin Berlin, Berlin, Germany

DOI: https://doi.org/10.1515/cipms-2017-0035 | Journal eISSN: 2300-6676 | Journal ISSN: 2084-980X

Journal RSS Feed

Language: English

Page range: 187 - 189

Submitted on: Sep 29, 2017

|

Accepted on: Dec 29, 2017

|

Published on: Mar 9, 2018

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

gastric adenocarcinoma,

hyperthermic intraperitoneal chemotherapy (HIPEC),

peritoneal metastasis,

peritoneal carcinomatosis,

GASTRIPEC trial

Related subjects:

Clinical medicine,

Clinical medicine, other,

Pharmacology, toxicology,

Pharmacy, other

© 2018 Beate Rau, Eva Pachmayr, Dusan Klos, Peter Thuss-Patience, Andreas Brandl, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 30 (2017): Issue 4 (December 2017)Next article